“Reversing Direct Oral Anticoagulants”

Slides:

Advertisements

Similar presentations

Educational Event 23rd & 24th January 2013

Advertisements

JOURNAL REVIEW Newer Antithrombotics in AF 1 Dr Ranjith MP Senior Resident Department of Cardiology Government Medical college Kozhikode.

Reversal of TSOACs 1 st Qatar Conference on Safe Anticoagulation Management (QCSAM): New Advances and Trends 28 February 2015 Scott Kaatz, DO, MSc, FACP,

What a Bloody Mess! A/Professor Kent Robinson Senior Staff Specialist, Liverpool & Campbelltown Hospitals.

NEW ORAL ANTICOAGULANTS

Jim Hoehns, Pharm.D.. Edoxaban Oral factor Xa inhibitor Bioavailability: 62% Tmax: 1-2 hrs Elimination: 50% renal Half-life: 9-11 hours.

Care of the Anti-coagulated Trauma Patient Julie Mayglothling, MD, FACEP Emergencies in Medicine March 8 th, 2012.

Adam M. Levine, DO, FACC Clinical Assistant Professor of Medicine Rowan University September 12 th, 2015.

ARISTOTLE Objectives Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority.

Unstable Angina and NSTEMIs: Management Principles Meira Louis Lisa Campfens.

Adding SubtractingMultiplyingDividingMiscellaneous.

Praxbind® - Idarucizumab

Anticoagulants and reversal

News You Can Use… Nick Gazda, PharmD Candidate 2016 Pete Koval, PharmD Cone Health Family Medicine December 2015.

Tim Nokes Haematologist Derriford Hospital Plymouth

Copyright © 2016 A Real Headache: Anticoagulation and A Subdural Hematoma COPYRIGHT © 2016, ALL RIGHTS RESERVED From the Publishers of.

The NEW ENGLAND JOURNAL of MEDICINE Idarucizumab for Dabigatran Reversal R3 김동연 / F. 김선혜.

TREATMENT OF ACUTE PULMONARY THROMBOEMB0LISM SEYED REZA SEYEDI.MD.

Managing reversal of direct oral anticoagulants in emergency situations Anticoagulation Education Task Force White Paper Walter Ageno1; Harry R. Büller2;

Anesthes. 2013;118(6): doi: /ALN.0b013e318289bcba Figure Legend:

Fadiea Al-Aieshy PhD-student, MSc Pharm

Difficult situations in anticoagulation after stroke

You can never be too Thin…. An Update on NOACs

Management of Bleeding with NOACS in Era of Specific Reversal Agents

Treatment of VTE 2016 Significant Changes University of Oklahoma

Volume 28, Issue 6, Pages (December 2012)

Anticoagulation in Atrial Fibrillation

In the name of God. Management trauma in elderly DR. NIKSOLAT GERIATRICIAN ASSISTANT PROFESSOR, IRAN UNIVERSITY OF MEDICAL SCIENCE.

Oral Anticoagulants and Reversal Agents

Anticoagulant Review Morning Report – April 25, 2018

Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.

Thrombosis, Cancer, and NOACs

Appropriate Stroke Prevention Strategies in Atrial Fibrillation

New Strategies to Prevent CV Events After Hospital Discharge

Emergency Management of NOAC Bleeding

POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF NOACS IN AF

Suggested approach to patients with dabigatran-associated bleeding

REVERSAL AGENTS FOR NOACS: Do WE NEED THEM in THE EP LAB?

New Perspectives in CAD and PAD: Weighing the Latest Evidence

Oral Anticoagulants in AFa,b A Brief History.

Therapeutic Strategies in the Management of Mild-to-Moderate Atopic Dermatitis.

Truman J. Milling, MD, Scott Kaatz, DO, MSc

Reversal of Direct Oral Anticoagulants (DOAC)

New Oral Anticoagulants and VTE Management

Reversal Strategies for VKA: Truths and Misconceptions

Menno V. Huisman, MD, PhD, John Fanikos, RPh, MBA

Oral Anticoagulation in AF

Evidence Supporting Idarucizumab for the Reversal of Dabigatran

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

DOACs and Urgent Bleeding

Neurosurgery and DOACs

Factor Xa Inhibitors in PAD

Oral Anticoagulant Reversal Agents

Cancer-Associated Thrombosis

Anticoagulant Reversal

Truman J. Milling, MD, Alex C. Spyropoulos, MD

New European Anticoagulant Approvals Will They Affect Practical Guidance?

Periprocedural Management of Patients on Anticoagulation

Which NOAC and When for Stroke Prevention in AF?

Nat. Rev. Cardiol. doi: /nrcardio

A Real Headache: Anticoagulation and a Subdural Hematoma

Adding with 9’s.

Adding with 10’s.

NOACs and Reversal Agents

VKA Reversal and LVADs.

Adding ____ + 10.

Arman Qamar et al. JACC 2018;71:

RE-ALIGN Randomized, Phase II Study to Evaluate the Safety and Pharmacokinetics of Oral Dabigatran Etexilate in Patients after Heart Valve Replacement.

Perspectives on Revised European Guidelines on Management of Bleeding and Coagulopathy Following Major Trauma.

Drug Summary Info Document Request / monitor Goal of therapy Action

Presentation transcript:

“Reversing Direct Oral Anticoagulants”

Disclosures

Level 1A evidence for reversal strategies for direct anticoagulants

Non-specific Reversal Strategies

PCCs

Tailored Reversal Agents

Idarucizumab: A Specific Reversal Agent For Dabigatran

RE-VERSE AD: Reversal of Dabigatran Anticoagulant Effect with Idarucizumab: Bleeding patients

Andexanet for Reversal of Both Direct and Indirect Xa Inhibitors

Andexanet: Designed to Reverse Activity of Factor Xa Inhibitors Nature Medicine (2013),19(4): 446-51

Summary Results From Healthy Older Volunteers

Summary For Andexanet